Nutra Pharma Corp Financials
This page shows Nutra Pharma Corp (NPHC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Nutra Pharma Corp passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nutra Pharma Corp generates $0.33 in operating cash flow (-$424K OCF vs -$1.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nutra Pharma Corp earns $-41.4 in operating income for every $1 of interest expense (-$878K vs $21K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Nutra Pharma Corp generated $246K in revenue in fiscal year 2024. This represents an increase of 19.8% from the prior year.
Nutra Pharma Corp's EBITDA was -$871K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 0.3% from the prior year.
Nutra Pharma Corp reported -$1.3M in net income in fiscal year 2024. This represents an increase of 7.7% from the prior year.
Nutra Pharma Corp held $36K in cash against $140K in long-term debt as of fiscal year 2024.
Nutra Pharma Corp had 7.10B shares outstanding in fiscal year 2024. This represents an increase of 0.5% from the prior year.
Nutra Pharma Corp's gross margin was 65.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 51.9 percentage points from the prior year.
Nutra Pharma Corp's operating margin was -356.6% in fiscal year 2024, reflecting core business profitability. This is up 74.9 percentage points from the prior year.
Nutra Pharma Corp's net profit margin was -522.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 155.9 percentage points from the prior year.
NPHC Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q4'22 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $82K+9.2% | $75K+45.0% | $52K+37.0% | $38K-19.8% | $47K-40.5% | $79K+220.8% | $25K-13.4% | $28K |
| Cost of Revenue | $20K-16.1% | $24K+27.7% | $19K-17.2% | $22K+9.7% | $21K-56.0% | $47K+13.5% | $41K-32.5% | $61K |
| Gross Profit | $23K-68.2% | $71K+113.7% | $33K-6.0% | $35K+32.7% | $27K+10.7% | $24K+245.9% | -$16K+49.2% | -$32K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $265K+3.9% | $255K-6.9% | $274K-17.0% | $331K+41.3% | $234K-78.6% | $1.1M+234.8% | $326K-6.4% | $349K |
| Operating Income | -$179K+3.2% | -$185K+15.8% | -$219K+25.7% | -$295K-110.6% | -$140K+86.3% | -$1.0M-331.8% | -$237K+30.7% | -$341K |
| Interest Expense | $6K+3.0% | $5K+4.1% | $5K+3.0% | $5K+1.9% | $5K+12.5% | $4K+3.0% | $4K+2.0% | $4K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$231K+11.4% | -$261K+29.0% | -$367K+14.0% | -$427K-75.6% | -$243K-107.5% | $3.2M+459.9% | $577K+189.4% | -$646K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
NPHC Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q4'22 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $599K+7.3% | $559K-11.4% | $631K+1.6% | $621K-3.1% | $640K-15.2% | $755K+9.3% | $691K-8.7% | $757K |
| Current Assets | $375K+20.6% | $311K-13.7% | $360K+12.4% | $320K+1.9% | $314K-5.9% | $334K-27.9% | $462K-8.4% | $505K |
| Cash & Equivalents | $36K | $0 | $0 | $0 | $0 | $0 | N/A | $10K |
| Inventory | $18K+3.6% | $17K-28.1% | $24K+27.7% | $19K-4.8% | $20K-18.1% | $24K-51.6% | $49K+18.5% | $42K |
| Accounts Receivable | N/A | $23K+2.5% | $23K+2.3% | $22K-1.5% | $22K+3.5% | $22K+0.4% | $22K-54.4% | $47K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $15.4M+0.2% | $15.4M+1.2% | $15.2M+2.5% | $14.8M+2.8% | $14.4M+9.7% | $13.1M-19.4% | $16.3M-3.9% | $17.0M |
| Current Liabilities | $15.3M+0.4% | $15.2M+1.4% | $15.0M+2.7% | $14.6M+3.0% | $14.2M+11.6% | $12.7M-21.3% | $16.1M-3.5% | $16.7M |
| Long-Term Debt | $140K-0.6% | $141K-0.6% | $142K-98.3% | $8.4M+5741.2% | $144K-98.2% | $8.2M | N/A | N/A |
| Total Equity | -$14.8M+0.1% | -$14.8M-1.8% | -$14.6M-2.6% | -$14.2M-3.1% | -$13.8M-11.2% | -$12.4M+20.7% | -$15.6M+3.6% | -$16.2M |
| Retained Earnings | -$76.2M-0.3% | -$76.0M-0.3% | -$75.7M-0.5% | -$75.4M-0.6% | -$74.9M-1.9% | -$73.6M+4.2% | -$76.8M+0.7% | -$77.4M |
NPHC Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q4'22 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$178K-1034.4% | $19K+120.4% | -$94K+45.3% | -$171K+8.1% | -$186K-244.7% | -$54K+67.3% | -$165K+41.9% | -$285K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$54K+67.3% | -$165K+41.9% | -$285K |
| Investing Cash Flow | $8K-75.6% | $34K+446.6% | -$10K-198.1% | $10K-88.0% | $84K+62.4% | $52K+6.6% | $48K+560.0% | -$11K |
| Financing Cash Flow | $206K+488.8% | -$53K-156.1% | $95K-44.7% | $171K+66.9% | $103K+3951.3% | $3K-97.6% | $107K-64.3% | $299K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NPHC Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q4'22 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 27.5%-66.8pp | 94.3%+30.3pp | 64.0%-29.3pp | 93.3%+36.9pp | 56.4%+26.1pp | 30.3%+97.0pp | -66.7%+47.1pp | -113.8% |
| Operating Margin | -218.5%+27.9pp | -246.4%+178.1pp | -424.5%+358.2pp | -782.6%-484.5pp | -298.1%+995.0pp | -1293.1%-332.6pp | -960.5%+239.2pp | -1199.7% |
| Net Margin | -282.0%+65.6pp | -347.6%+362.4pp | -710.0%+421.5pp | -1131.5%-614.7pp | -516.8%-4608.6pp | 4091.8%+1747.7pp | 2344.2%+4615.6pp | -2271.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -38.5%+8.1pp | -46.7%+11.5pp | -58.2%+10.6pp | -68.8%-30.8pp | -38.0%-466.1pp | 428.1%+344.6pp | 83.6%+168.9pp | -85.3% |
| Current Ratio | 0.020.0 | 0.020.0 | 0.020.0 | 0.020.0 | 0.020.0 | 0.030.0 | 0.030.0 | 0.03 |
| Debt-to-Equity | -0.010.0 | -0.010.0 | -0.01+0.6 | -0.59-0.6 | -0.01+0.7 | -0.66+0.4 | -1.040.0 | -1.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -68.4%+603.0pp | -671.5%+330.4pp | -1001.8% |
Note: Shareholder equity is negative (-$14.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Nutra Pharma Corp's annual revenue?
Nutra Pharma Corp (NPHC) reported $246K in total revenue for fiscal year 2024. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nutra Pharma Corp's revenue growing?
Nutra Pharma Corp (NPHC) revenue grew by 19.8% year-over-year, from $206K to $246K in fiscal year 2024.
Is Nutra Pharma Corp profitable?
No, Nutra Pharma Corp (NPHC) reported a net income of -$1.3M in fiscal year 2024, with a net profit margin of -522.0%.
What is Nutra Pharma Corp's earnings per share (EPS)?
Nutra Pharma Corp (NPHC) reported diluted earnings per share of $0.00 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Nutra Pharma Corp's EBITDA?
Nutra Pharma Corp (NPHC) had EBITDA of -$871K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nutra Pharma Corp have?
As of fiscal year 2024, Nutra Pharma Corp (NPHC) had $36K in cash and equivalents against $140K in long-term debt.
What is Nutra Pharma Corp's gross margin?
Nutra Pharma Corp (NPHC) had a gross margin of 65.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nutra Pharma Corp's operating margin?
Nutra Pharma Corp (NPHC) had an operating margin of -356.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Nutra Pharma Corp's net profit margin?
Nutra Pharma Corp (NPHC) had a net profit margin of -522.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Nutra Pharma Corp's operating cash flow?
Nutra Pharma Corp (NPHC) generated -$424K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Nutra Pharma Corp's total assets?
Nutra Pharma Corp (NPHC) had $599K in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Nutra Pharma Corp have outstanding?
Nutra Pharma Corp (NPHC) had 7.10B shares outstanding as of fiscal year 2024.
What is Nutra Pharma Corp's current ratio?
Nutra Pharma Corp (NPHC) had a current ratio of 0.02 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Nutra Pharma Corp's debt-to-equity ratio?
Nutra Pharma Corp (NPHC) had a debt-to-equity ratio of -0.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nutra Pharma Corp's return on assets (ROA)?
Nutra Pharma Corp (NPHC) had a return on assets of -214.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Nutra Pharma Corp's cash runway?
Based on fiscal year 2024 data, Nutra Pharma Corp (NPHC) had $36K in cash against an annual operating cash burn of $424K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nutra Pharma Corp's debt-to-equity ratio negative or unusual?
Nutra Pharma Corp (NPHC) has negative shareholder equity of -$14.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nutra Pharma Corp's Piotroski F-Score?
Nutra Pharma Corp (NPHC) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nutra Pharma Corp's earnings high quality?
Nutra Pharma Corp (NPHC) has an earnings quality ratio of 0.33x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nutra Pharma Corp cover its interest payments?
Nutra Pharma Corp (NPHC) has an interest coverage ratio of -41.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.